FICHIT

Je m'inscris

POXEL

0/5 (0 note(s))
Note donnée : aucune
Paris
176
Develops innovative drugs for metabolic diseases, currently focused on type 2 diabetes.
Our lead compound, Imeglimin, which targets mitochondrial dysfunction, has completed Phase 2 clinical development for type 2 diabetes in the EU and US, and has entered Phase 2b clinical development in Japan. This product has demonstrated a robust efficacy and an excellent safety profile in 7 phase 2 trials in more than 600 patients, as a monotherapy treatment (primary and secondary endpoints met in a Phase 2b dose-ranging trial), as well as in combination with the 2 most important drugs prescribed to T2D patients, metformin and sitagliptin.
KUHN Thomas
www.poxel.com
POXEL:FP

Fiche créée le 10/04/2016 par Guillaume   vue 10 fois.